MCID: GLM004
MIFTS: 49

Gliomatosis Cerebri malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Gliomatosis Cerebri

Aliases & Descriptions for Gliomatosis Cerebri:

Name: Gliomatosis Cerebri 12 50 56 52 14 69
Neoplasms, Neuroepithelial 42
Astrocytosis Cerebri 12

Characteristics:

Orphanet epidemiological data:

56
gliomatosis cerebri
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:6128
MeSH 42 D018302
NCIt 47 C4318
SNOMED-CT 64 26138003
Orphanet 56 ORPHA251582
UMLS via Orphanet 70 C0334576
ICD10 via Orphanet 34 C71.0
UMLS 69 C0334576

Summaries for Gliomatosis Cerebri

NIH Rare Diseases : 50 gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. it involves at least three sections (lobes) within the main part of the brain (cerebrum). it may also affect both sides of the cerebrum as well as the nerve cells within the brain (grey matter). there are two types of gliomatosis cerebri. type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. signs and symptoms of gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures. because this type of cancer can be found in many areas of the brain, it can be challenging to treat. treatment might include surgery to remove areas of the brain affected (when possible), radiation therapy, and chemotherapy. last updated: 7/21/2016

MalaCards based summary : Gliomatosis Cerebri, also known as neoplasms, neuroepithelial, is related to papillary tumor of the pineal region and hypogonadotropic hypogonadism-retinitis pigmentosa syndrome, and has symptoms including headache, seizures and sensory manifestations. An important gene associated with Gliomatosis Cerebri is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MicroRNAs in cancer. The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and breast, and related phenotype is normal.

Wikipedia : 71 Gliomatosis cerebri (infiltrative diffuse astrocytosis) is a rare primary brain tumor. It is commonly... more...

Related Diseases for Gliomatosis Cerebri

Diseases related to Gliomatosis Cerebri via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
id Related Disease Score Top Affiliating Genes
1 papillary tumor of the pineal region 10.3 GFAP IDH1
2 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.2 GFAP IDH1
3 bronchial mucus gland adenoma 10.2 GFAP PTEN
4 cystic lymphangioma 10.2 IDH1 PTEN
5 epidermal appendage tumor 10.2 GFAP PTEN
6 testis refractory cancer 10.2 IDH1 TP53
7 pineal gland astrocytoma 10.2 IDH1 TP53
8 cystinosis, nephropathic 10.2 IDH1 TP53
9 aneurysm of sinus of valsalva 10.2 GFAP PTEN
10 liver fibrosarcoma 10.2 GFAP TP53
11 cervical adenoid cystic carcinoma 10.2 GFAP TP53
12 hypothalamic neoplasm 10.2 GFAP NES
13 angiofollicular lymph hyperplasia 10.2 GFAP NES
14 bronchitis 10.2 GFAP TP53
15 bile duct clear cell adenocarcinoma 10.2 GFAP TP53
16 melanotic neurilemmoma 10.2 GFAP IDH1
17 cervical benign neoplasm 10.2 GFAP TP53
18 childhood kidney cell carcinoma 10.2 GFAP NES
19 clear cell meningioma 10.2 GFAP TP53
20 nephrogenic adenoma of urinary bladder 10.2 GFAP NES
21 porokeratosis 10.2 GFAP TP53
22 blood group incompatibility 10.2 GFAP TP53
23 brain stem angioblastoma 10.2 IDH1 TP53
24 mast-cell sarcoma 10.2 GFAP TP53
25 olfactory neuroblastoma 10.2 GFAP TP53
26 mixed epithelial stromal tumour 10.2 GFAP TP53
27 breast ductal carcinoma 10.2 PTEN TP53
28 superior vena cava syndrome 10.2 GFAP NES
29 pineoblastoma 10.2 GFAP TP53
30 brain stem astrocytic neoplasm 10.2 GFAP TP53
31 osteopetrosis, autosomal recessive 8 10.2 GFAP NES
32 calcific tendinitis 10.2 GFAP NES
33 adult syndrome 10.2 PTEN TP53
34 auricular cancer 10.2 GFAP NES
35 villoglandular endometrial endometrioid adenocarcinoma 10.2 PTEN TP53
36 childhood choroid plexus cancer 10.2 GFAP TP53
37 bronchiolitis obliterans 10.2 GFAP NES
38 dysgerminoma of ovary 10.2 GFAP NES
39 encephalitis 10.1
40 pediculus humanus corporis infestation 10.1 GFAP NES
41 arthus reaction 10.1 GFAP TP53
42 pancreatic cancer 10.1 GFAP TP53
43 plasmodium ovale malaria 10.1 GFAP TP53
44 hair disease 10.1 NES TP53
45 urethral verrucous carcinoma 10.1 PTEN TP53
46 pacinian tumor 10.1 GFAP TP53
47 glioma susceptibility 2 10.1 EGFR PTEN
48 clear cell variant infiltrating bladder urothelial carcinoma 10.1 GFAP TP53
49 wolffian adnexal neoplasm 10.1 EGFR TP53
50 focal cortical dysplasia, taylor balloon cell type 10.1 GFAP PTEN

Graphical network of the top 20 diseases related to Gliomatosis Cerebri:



Diseases related to Gliomatosis Cerebri

Symptoms & Phenotypes for Gliomatosis Cerebri

UMLS symptoms related to Gliomatosis Cerebri:


headache, seizures, sensory manifestations

MGI Mouse Phenotypes related to Gliomatosis Cerebri:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.02 EGFR GFAP INA PTEN TP53

Drugs & Therapeutics for Gliomatosis Cerebri

Drugs for Gliomatosis Cerebri (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 699)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
8
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
9
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 52-24-4 5453
10
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
11
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
13
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
14
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
15
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
16
Nicotine Approved Phase 4 54-11-5 942 89594
17 Piracetam Approved Phase 4,Phase 2 7491-74-9
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
20 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
24 Neuroprotective Agents Phase 4,Phase 2,Phase 1
25 Nootropic Agents Phase 4,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
32 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
33 Etiracetam Phase 4,Phase 2
34 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
46 Hydroxyitraconazole Phase 4,Phase 1
47 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 1
50 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2122)
id Name Status NCT ID Phase
1 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
2 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
3 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
4 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
5 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4
6 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
7 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4
8 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4
9 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
10 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
11 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
12 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
13 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3
14 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3
15 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
16 Carboplatin Periocular Injection for Retinoblastoma Unknown status NCT02137928 Phase 3
17 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
18 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Unknown status NCT00499616 Phase 3
19 Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma Unknown status NCT00276731 Phase 3
20 Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors Unknown status NCT00278239 Phase 3
21 Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma Unknown status NCT00416676 Phase 3
22 Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant Unknown status NCT00417053 Phase 3
23 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3
24 Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma Unknown status NCT00410631 Phase 3
25 Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma Unknown status NCT00030719 Phase 3
26 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Unknown status NCT01149109 Phase 3
27 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
28 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3
29 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3
30 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
31 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma Completed NCT00335738 Phase 3
32 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3
33 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma Completed NCT00079417 Phase 3
34 Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma Completed NCT00072384 Phase 3
35 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
36 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3
37 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3
38 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3
39 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
40 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3
41 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3
42 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma Completed NCT00004188 Phase 3
43 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
44 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
45 Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor Completed NCT00006461 Phase 3
46 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3
47 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed NCT00033293 Phase 3
48 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3
49 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3
50 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma Completed NCT00336024 Phase 3

Search NIH Clinical Center for Gliomatosis Cerebri

Cochrane evidence based reviews: neoplasms, neuroepithelial

Genetic Tests for Gliomatosis Cerebri

Anatomical Context for Gliomatosis Cerebri

MalaCards organs/tissues related to Gliomatosis Cerebri:

39
Brain, Spinal Cord, Breast, Pituitary

Publications for Gliomatosis Cerebri

Articles related to Gliomatosis Cerebri:

(show top 50) (show all 228)
id Title Authors Year
1
Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France. ( 27466787 )
2016
2
Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. ( 26017099 )
2016
3
Radiology Case of the Month: Gliomatosis Cerebri. ( 27598892 )
2016
4
Pediatric Gliomatosis Cerebri: A Review of 15 Years. ( 26239491 )
2016
5
Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. ( 26744350 )
2016
6
Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity. ( 26744347 )
2016
7
Perioperative risk assessment of patients with gliomatosis cerebri. ( 27836704 )
2016
8
Gliomatosis cerebri: no evidence for a separate brain tumor entity. ( 26493382 )
2016
9
Gliomatosis cerebri in L-2-hydroxyglutaric aciduria. ( 25997888 )
2015
10
Gliomatosis cerebri having a poor performance status without recurrence after radiotherapy: a single institutional experience. ( 25569296 )
2015
11
Gliomatosis cerebri: Case series of six cases with review of literature. ( 26752659 )
2015
12
Gliomatosis cerebri in a 12-year-old patient. ( 25662824 )
2015
13
Gliomatosis cerebri with spinal metastasis presenting with chronic meningitis in two boys. ( 26318497 )
2015
14
"Fungimitosis": Invasive fulminant Aspergillus brain infection mimicking gliomatosis cerebri. ( 26053824 )
2015
15
Gliomatosis cerebri mimicking encephalitis evaluated using fluorine-18 fluorodeoxyglucose: Positron emission tomography/computed tomography. ( 25589818 )
2015
16
Pediatric gliomatosis cerebri mimicking tubercular encephalitis. ( 26962350 )
2015
17
Corticosteroid sensitivity in gliomatosis cerebri delays diagnosis. ( 25922538 )
2015
18
A comparison of clinical, magnetic resonance imaging and pathological findings in dogs with gliomatosis cerebri, focusing on cases with minimal magnetic resonance imaging changes(a8!) ( 24945683 )
2014
19
Patterns of presentation and failure in patients with gliomatosis cerebri treated with partial-brain radiation therapy. ( 24845411 )
2014
20
Clinical manifestations and imaging characteristics of gliomatosis cerebri with pathological confirmation. ( 24969874 )
2014
21
Gliomatosis cerebri: a review. ( 24390814 )
2014
22
Gliomatosis Cerebri Type 1 with Extensive Involvement of the Spinal Cord and BRAF V600E Mutation. ( 24353007 )
2014
23
Gliomatosis cerebri mimicking acute viral encephalitis and with malignant transformation of partial lesions: A case report. ( 25120625 )
2014
24
Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide. ( 25189790 )
2014
25
Exclusive radiotherapy for gliomatosis cerebri: long-term follow-up at a single institution. ( 24474572 )
2014
26
Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri. ( 25408934 )
2014
27
Gliomatosis cerebri mimicking viral encephalitis in a 4-year-old child. ( 24717581 )
2014
28
Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases. ( 23306961 )
2013
29
Letter to the editor: gliomatosis cerebri. ( 23198839 )
2013
30
Bilateral ptosis as initial presentation of gliomatosis cerebri: case report. ( 23427031 )
2013
31
Gliomatosis cerebri: clinical characteristics, management, and outcomes. ( 23341100 )
2013
32
18F FDG PET/CT in a child with gliomatosis cerebri. ( 23122744 )
2013
33
Teaching NeuroImages: diffuse cerebral neurosarcoidosis mimicking gliomatosis cerebri. ( 23940026 )
2013
34
Juvenile parkinsonism as an initial manifestation of gliomatosis cerebri. ( 24158273 )
2013
35
Uncal decompression in gliomatosis cerebri. ( 23618524 )
2013
36
Response: gliomatosis cerebri. ( 23495379 )
2013
37
Infiltration of the Optic Chiasm, Nerve, and Disc by Gliomatosis Cerebri. ( 23287703 )
2013
38
Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. ( 22341931 )
2012
39
IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. ( 21481010 )
2012
40
Subcutaneous tumor seeding after biopsy in gliomatosis cerebri. ( 21837541 )
2012
41
Gliomatosis cerebri in two dogs. ( 22843831 )
2012
42
Gliomatosis cerebri. ( 22230515 )
2012
43
Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri. ( 21929658 )
2012
44
A rare case of gliomatosis cerebri presenting as dementia. ( 22690056 )
2012
45
Presentation patterns and outcome of gliomatosis cerebri. ( 22740882 )
2012
46
An initial exploration of surgery following radiotherapy for the treatment of gliomatosis cerebri. ( 23253734 )
2012
47
MRI features of gliomatosis cerebri in a dog. ( 22413939 )
2012
48
Gliomatosis cerebri diagnostic challenge: two case reports. ( 21881469 )
2011
49
NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. ( 21710625 )
2011
50
A^A^C-Methionine or A^A^C-Choline PET is superior to MRI in the evaluation of gliomatosis cerebri. ( 21220976 )
2011

Variations for Gliomatosis Cerebri

Expression for Gliomatosis Cerebri

Search GEO for disease gene expression data for Gliomatosis Cerebri.

Pathways for Gliomatosis Cerebri

GO Terms for Gliomatosis Cerebri

Cellular components related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.13 GFAP INA NES
2 intermediate filament cytoskeleton GO:0045111 8.8 GFAP INA NES

Biological processes related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 learning or memory GO:0007611 9.16 EGFR PTEN
2 response to organic cyclic compound GO:0014070 9.13 EGFR IDH1 PTEN
3 phosphatidylinositol-mediated signaling GO:0048015 8.8 EGFR PTEN TP53

Molecular functions related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.13 EGFR PTEN TP53
2 identical protein binding GO:0042802 8.92 EGFR GFAP PTEN TP53

Sources for Gliomatosis Cerebri

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....